Screening for prostate cancer remains controversial.

BMJ (Clinical research ed.)

Volumn 339, Issue , 2009, Pages

  Stark, Jennifer R ^a   Mucci, Lorelei ^a   Rothman, Kenneth J ^a   Adami, Hans Olov ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; CANCER DIAGNOSIS; COST; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATE TUMOR; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARD; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70349573925     PISSN: None     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.b3601     Document Type: Article

References (0)